1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAdapting and evaluating smartphone app-enhanced home blood pressure monitoring among pregnant women in Ghana is sponsored by Fogarty International Center at NIH. This study aims to adapt and evaluate a Bluetooth blood pressure monitor and smartphone app-enhanced home blood pressure monitoring intervention among pregnant women in Ghana.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Adapting and evaluating smartphone app-enhanced home blood pressure monitoring among pregnant women in Ghana - Fogarty International Center @ NIH Adapting and evaluating smartphone app-enhanced home blood pressure monitoring among pregnant women in Ghana Search and filter all Fogarty grants Search all NIH grants and grantees using NIH RePORTER The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Project Information in NIH RePORTER Adapting and evaluating smartphone app-enhanced home blood pressure monitoring among pregnant women in Ghana University of Michigan at Ann Arbor Principal Investigator(s) (PI) Lawrence, Emma Rachel; Oppong, Samuel Antwi Project Contact Information This study will leverage widespread smartphone use in urban Ghana together with accessible technology adapted to the Ghanaian setting to overcome barriers to home blood pressure monitoring in pregnancy.
The study will adapt and measure feasibility and acceptability (R21 Phase) and evaluate adherence and clinical response (R33 Phase) of a Bluetooth blood pressure monitor and smartphone app-enhanced home blood pressure monitoring intervention among pregnant women in Ghana.
Implementing home blood pressure monitoring in a low-and-middle-income country setting will provide a critical step toward frequent assessment of blood pressures, earlier diagnosis of hypertensive disorders of pregnancy, and prevention of serious maternal morbidity and mortality. Related World Regions / Countries Related Global Health Research Topics Maternal and child health
According to the current listing, eligibility includes: Universities, particularly those with expertise in mobile health and maternal health research. Confirm the full requirements in the official notice before applying.
Adapting and evaluating smartphone app-enhanced home blood pressure monitoring among pregnant women in Ghana is funded by Fogarty International Center at NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article